Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Greece eyes migrant repatriation centres outside the EU - 2The year's first meteor shower and supermoon clash in January skies
- 3Explainer-What Novo Nordisk's weight-loss pill approval means for company, patients
- 4Instructions to Explore the Therapy Choices for Cellular breakdown in the lungs
- 512 times rockets and spacecraft crashed and burned in 2025
- Far-right leader Le Pen to attend Brigitte Bardot's funeral
- Vote in favor of Your Number one BWM Vehicles
- The Force of Systems administration: Individual Examples of overcoming adversity
- 2 of Earth's rarest lightning phenomena captured simultaneously in once-in-a-lifetime photo
- Building a Flourishing Business: Illustrations from Business people
- Former United Launch Alliance CEO Tory Bruno joins competitor Blue Origin for national security projects
- See the famous winged horse Pegasus fly in the autumn night sky
- Step by step instructions to Buy a Jeep Wrangler on a Senior's Spending plan
- Rick Steves' Favorite Time To Visit Spain Has Lower Prices And Fewer Crowds
